Doxorubicin

Generic Name: Doxorubicin

Brand Names: Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₁

CAS Number: 23214-92-8

Unique Ingredient Identifier: 80168379AG

Background: Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication: Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions: AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor

Associated Therapies: -

Clinical Trials

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Phase 3

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: cyclophosphamide
Biological: rituximab
Drug: doxorubicin
Drug: prednisone
Drug: vincristine
Radiation: tositumomab

First Posted Date: 2003-01-27

Last Posted Date: 2024-06-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 571

Registration Number: NCT00006721

Locations: 🇺🇸
Northside Hospital Cancer Center, Atlanta, Georgia, United States
🇺🇸
Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

and more 254 locations

Surgery in Treating Children With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Procedure: conventional surgery
Biological: filgrastim
Radiation: radiation therapy
Biological: sargramostim
Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Procedure: adjuvant therapy

First Posted Date: 2003-01-27

Last Posted Date: 2017-03-13

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 968

Registration Number: NCT00003119

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States

and more 231 locations

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

Phase 3

Completed

Conditions: Kidney Cancer

Interventions: Biological: dactinomycin
Drug: vincristine sulfate
Biological: filgrastim
Drug: doxorubicin hydrochloride
Procedure: conventional surgery
Drug: cyclophosphamide
Radiation: radiation therapy
Drug: etoposide

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-25

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 3031

Registration Number: NCT00002611

Locations: 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸
Maine Children's Cancer Program, Scarborough, Maine, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States

and more 231 locations

Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-20

Lead Sponsor: Mount Vernon Cancer Centre at Mount Vernon Hospital

Target Recruit Count: 850

Registration Number: NCT00041210

Locations: 🇬🇧
Pinderfields General Hospital, Wakefield, Scotland, United Kingdom
🇬🇧
Aintree University Hospital, Liverpool, England, United Kingdom
🇬🇧
City Hospital - Birmingham, West Bromwich, England, United Kingdom

and more 34 locations

Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer

Phase 3

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Commissie Voor Klinisch Toegepast Onderzoek

Target Recruit Count: 250

Registration Number: NCT00003696

Locations: 🇳🇱
Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands

Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma

Phase 3

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Commissie Voor Klinisch Toegepast Onderzoek

Target Recruit Count: 450

Registration Number: NCT00028886

Locations: 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇳🇱
Isala Klinieken - locatie Sophia, Zwolle, Netherlands
🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands

and more 14 locations

Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Commissie Voor Klinisch Toegepast Onderzoek

Target Recruit Count: 400

Registration Number: NCT00028717

Locations: 🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
🇳🇱
Medisch Spectrum Twente, Enschede, Netherlands
🇳🇱
Daniel Den Hoed Cancer Center at Erasmus Medical Center, Rotterdam, Netherlands

and more 10 locations

Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: European Infant Neuroblastoma Study Group - 1999

Registration Number: NCT00025649

Locations: 🇸🇪
Ostra Sjukhuset, Gothenburg, Sweden
🇫🇷
Centre Hospitalier Regional de Purpan, Toulouse, France
🇳🇴
Rikshospitalet University Hospital, Oslo, Norway

and more 8 locations

Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: European Infant Neuroblastoma Study Group - 1999

Registration Number: NCT00025610

Locations: 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇦🇹
St. Anna Children's Hospital, Vienna, Austria
🇧🇪
Universitair Ziekenhuis Gent, Ghent, Belgium

and more 9 locations

Chemotherapy Plus Surgery in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 450

Registration Number: NCT00003013

Locations: 🇦🇹
Kaiser Franz Josef Hospital, Vienna, Austria
🇨🇿
Radiotherapy Institute, Ostrava-Poruba, Czech Republic
🇸🇰
St. Elizabeth Cancer Institute Hospital, Bratislava, Slovakia

and more 25 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy